ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer 04 Jun 2019
ASCO 2017: Adding abiraterone to standard treatment improves prostate cancer survival by almost 40% 03 Jun 2017